Dermatologicals
Refine Search
Pharmaceutical
Beleaguered Canadian firm Valeant Pharmaceuticals International (TSX: VRX) has entered into an agreement to sell its Obagi Medical Products business for $190 million in cash to Haitong International Zhonghua Finance Acquisition Fund I. 18 July 2017
Pharmaceutical
Spain's leading drugmaker Almirall has launched a new research project, dubbed Nano4Derm, to investigate ways that nanomedicine can be used to treat dermatological diseases. 18 July 2017
Biotechnology
Positive five year efficacy and safety results for Cosentyx (secukinumab) from a Phase III long-term extension study in patients with moderate-to-severe plaque psoriasis have been released. 15 July 2017
Biotechnology
After cashing in a priority review voucher with the US FDA, healthcare giant Johnson & Johnson's biopharmaceutical arm Janssen Biotech has been given approval to market Tremfya as a treatment for moderate to severe plaque psoriasis. 14 July 2017
Biotechnology
The National Institute for Health and Care Excellence (NICE) today published guidance recommending approval of three drugs for the treatment of plaque psoriasis in children and young people. 12 July 2017
Pharmaceutical
Monday has been a painful day for Almirall, Spain’s largest drugmaker, which looked set to close the day’s trading having lost a quarter of its share value. 10 July 2017
Pharmaceutical
Spain’s leading drugmaker Almirall has received European clearance to market Skilarence (dimethyl fumarate), a new oral formulation of a type of fumaric acid ester, for the treatment of patients with moderate-to-severe chronic plaque psoriasis. 27 June 2017
Pharmaceutical
Danish drugmaker LEO Pharma today announced that it appointed Chris Posner as executive vice president Region US and president and chief executive LEO Pharma Inc. 23 June 2017
Biotechnology
The Institute of Clinical and Economic Review (ICER) has issued a Final Evidence Report and summary of a public meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) that concludes Dupixent (dupilumab) offers good long-term value for patients with moderate-to-severe atopic dermatitis. 12 June 2017
Biotechnology
The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined in two early benefit assessments whether Novartis’ Cosentyx (secukinumab) and Taltz (ixekizumab) from Eli Lilly offer an added benefit for patients in comparison with the appropriate comparator therapies. 5 June 2017
Pharmaceutical
A unique collaboration has been announced today between Spanish and Danish drugmakers that aims to advance understanding of skin diseases by setting a new standard for skin sampling. 30 May 2017
Biotechnology
The US Food and Drug Administration has accepted the Biologics License Application (BLA) for tildrakizumab. 24 May 2017
Pharmaceutical
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued positive recommendations for six new medicines at its May meeting. 19 May 2017
Biotechnology
The USA’s Institute for Clinical and Economic Review (ICER), a non-profit organization, has released an Evidence Report assessing the comparative clinical effectiveness and value of dupilumab and crisaborole for the treatment of atopic dermatitis. 14 May 2017
Pharmaceutical
Valeant Pharmaceuticals International has had to endure a 95% reduction in its share price value in the last two years, but there was finally some encouraging news for investors as the company announced its latest quarterly results. 9 May 2017
Pharmaceutical
There were positive aspects of Almirall’s first quarter financial results but investors are likely to have been most struck by a 10% drop in profits as the company’s share price fell by 4% to 15.93 euros in five hours of trading after the figures were announced on Monday. 8 May 2017
Generics
Generic drugmaker Perrigo lost 5% in its stock-market value on Wednesday, closing at $72.35, amid news of a raid on its corporate offices in relation to the US Department of Justice Antitrust Division investigation into price fixing. 4 May 2017
Biotechnology
Eli Lilly says that Taltz (ixekizumab) has been recommended by the National Institute for Health and Care Excellence (NICE) for use as a treatment option within the NHS England. 26 April 2017
Pharmaceutical
Crescita Therapeutics has entered into a development and commercialization license agreement with the Canadian subsidiary of Taro Pharmaceutical Industries. 25 April 2017
Pharmaceutical
US health care giant Johnson & Johnson kicked of the first-quarter financial results with a mixed bunch of figures. The coming week will see results from more pharma and biotech majors, including AbbVie, Amgen, Biogen and Bristol-Myers in the USA, as well as AstraZeneca, Bayer, GSK, Novartis and Roche in Europe. Also attracting attention last week was Ultragenyx with its burosumab, and disappointing news for AbbVie’s veliparib. There was also news from Canada’s Valeant Pharmaceuticals International regarding launch plans for its new psoriasis treatment Siliq. 23 April 2017
Biotechnology
Colorado, USA-based biotech Enveda Biosciences, which is using AI to translate nature into new medicines, has announced an oversubscribed $130 million Series C funding round led by Kinnevik and FPV. 22 November 2024
Biotechnology
The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) inhibitors across the seven major pharmaceutical markets (7MM; USA, France, Germany, Italy, Spain, UK and Japan). 20 November 2024
Biotechnology
Johnson & Johnson and partner Protagonist Therapeutics have reported positive topline results from two Phase III studies testing a first-in-class oral peptide. 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License Application (sBLA) for Dupixent(dupilumab), Regeneron and partner Sanofi revealed late Friday. 18 November 2024
Pharmaceutical
Danish dermatology specialist LEO Pharma today announced that Swissmedic, Switzerland’s national regulatory agency for approving and overseeing therapeutic products, has granted marketing approval for Anzupgo (delgocitinib) cream. 14 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Pharmaceutical
Almirall, the Spain-based biopharma, reported a 7.9% increase in net sales for the first nine months of 2024, reaching 728 million euros ($775 million), and an EBITDA rise of 2.9% to $152 million. 11 November 2024
Biotechnology
New research has been published in the Journal of Allergy and Clinical Immunology (JACI) that shows treatment with amlitelimab, an anti-OX40 ligand antibody, significantly reduced symptoms of atopic dermatitis (AD) and was maintained even after treatment stopped. 9 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted a Rare Pediatric disease designation for BPM31510T, an investigational treatment for epidermolysis (EB) from BPGbio. 4 November 2024
Pharmaceutical
Denmark’s privately-held dermatology specialist LEO Pharma and Japan’s Kyowa Kirin have revealed that they will terminate the distribution and co-promotion agreement for the psoriasis vulgaris treatment Dovobet Ointment, Gel, and Foam (calcipotriol hydrate / betamethasone dipropionate) in Japan on December 31, 2024. 1 November 2024
Biotechnology
Regeneron Pharmaceuticals today announced financial results for the third quarter of 2024 that beat expectations, but still saw its share price fall more than 6% to $866 in early trading. 31 October 2024
Biotechnology
Treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment, says US healthcare giant Johnson & Johnson. 25 October 2024
Biotechnology
New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with Dupixent (dupilumab). 25 October 2024
Biosimilars
Iceland-based Alvotech and the US unit of Israel’s of Teva Pharmaceutical Industries today revealed that that the US Food and Drug Administration (FDA) has approved Selarsdi (ustekinumab-aekn) in a new presentation 22 October 2024
Pharmaceutical
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
The US Food and Drug Administration (FDA) has approved a 2mL pre-filled syringe and pre-filled autoinjector, each containing 320mg of Belgian drugmaker UCB’s Bimzelx (bimekizumab-bkzx), to treat psoriasis. 14 October 2024
Biosimilars
Bio-Thera Solutions and Hungary’s Gedeon Richter have reached an exclusive commercialization and license agreement. 14 October 2024
Biotechnology
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze